Table 2. Clinical outcomes in the subgroup analysis based on patients with ERCP and glucagon (Group 1) to ERCP without glucagon (Group 2) after propensity matching.
| Before matching | After matching | |||||
| Primary outcome | ERCP w glucagon (Group A) N = 9008 | ERCP w/o glucagon (Group B) N = 256578 | RR (95 % CI) | ERCP w glucagon (Group A) N = 9008 | ERCP wo glucagon (Group B) N = 9008 | RR (95 % CI) |
| GIB | 100 (1.11) | 3420 (1.33) | 0.83 (0.68 – 1.01) | 100 (1.11) | 149 (1.65) | 0.67 (0.52 – 0.86) |
| PEP | 638 (7.08) | 27725 (10.81) | 0.66 (0.61 – 0.71) | 638 (7.08) | 995 (11.05) | 0.64 (0.58 – 0.71) |
| GI Perforation | 16 (0.18) | 627 (0.24) | 0.73 (0.44 – 1.19) | 16 (0.18) | 25 (0.28) | 0.64 (0.34 – 1.20) |
| Hyperglycemia | 30 (0.33) | 1,415 (0.55) | 0.60 (0.42–0.87) | 30 (0.33) | 46 (0.51) | 0.65 (0.41–1.03) |
| Hyperkalemia | 95 (1.55) | 2017 (0.79) | 1.34 (1.09–1.64) | 95 (1.06) | 114 (1.27) | 0.83 (0.64–1.09) |
| Hospitalization | 1243 (13.80) | 104237 (40.63) | 0.34 (0.32 – 0.36) | 1243 (13.80) | 3676 (40.81) | 0.34 (0.32 – 0.36) |
| Death | 163 (1.81) | 4904 (1.91) | 0.95 (0.81 – 1.11) | 163 (1.81) | 202 (2.24) | 0.81 (0.66 – 0.99) |
ERCP, endoscopic retrograde cholangiopancreatography; CI, confidence interval; RR, risk ratio; GIB, gastrointestinal bleeding; PEP, post-ERCP pancreatitis.